Trial of Buprenorphine/Naloxone for Opiate Dependence - 2

This study has been completed.

First Received: September 20, 1999 Last Updated: June 23, 2005 History of Changes

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) University of Pennsylvania
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000353

Purpose

The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate dependence treatment.

Condition	Intervention	Phase
Opioid-Related Disorders Substance-Related Disorders	Drug: Buprenorphine/naloxone	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Efficacy/Safety Trial of Buprenorphine/Nx for Opiate Dependence

Resource links provided by NLM:

Drug Information available for: Buprenorphine Buprenorphine hydrochloride Naloxone hydrochloride Naloxone

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	19 Years to 57 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000353

Locations

United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Pennsylvania

Investigators

Principal Investigator:

Charles O'Brien, M.D., Ph.D.

PDVAMC Treatment Research Center

More Information

No publications provided

Study ID Numbers:	NIDA-3-0012-2, Y01-3-0012-2
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000353 History of Changes
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Buprenorphine
Mental Disorders
Narcotic Antagonists
Substance-Related Disorders
Central Nervous System Depressants
Disorders of Environmental Origin

Narcotics
Peripheral Nervous System Agents
Analgesics
Opioid-Related Disorders
Analgesics, Opioid
Naloxone

Additional relevant MeSH terms:

Disease
Narcotic Antagonists
Physiological Effects of Drugs
Central Nervous System Depressants
Disorders of Environmental Origin
Narcotics
Opioid-Related Disorders
Pharmacologic Actions
Naloxone
Buprenorphine

Pathologic Processes
Mental Disorders
Sensory System Agents
Therapeutic Uses
Substance-Related Disorders
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents
Analgesics, Opioid

ClinicalTrials.gov processed this record on July 02, 2009